|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Supplemental table 2 Summary of the 33 patients with HBV reactivation.** | | | | | | | | | | | | | | | |  |  |
| **Patient** | **age** (years) | **At diagnosis of MM** | | | | | | | | |  | **at the time of HBV reactivation** | | | | |  |
| **ALT** (U/L) | **AST** (U/L) | **TBIL** (umo/l) | **HBsAg** | **HBsAb** | **HBeAg** | **HBeAb** | **HBcAb** | **HBV DNA** (IU/ml) |  | **ALT** (U/L) | **AST** (U/L) | **TBIL** (umo/l) | **HBV DNA** (IU/ml) | | **anti-HBV theapy** |
| 1 | 52 | 71.4 | 39.5 | 6.9 | + | + | - | + | + | 7.34E+04 |  | 87.5 | 33.4 | 8.7 | 6.44E+06 | | TAF |
| 2 | 70 | 18.5 | 12.5 | 5.4 | + | - | - | + | + | 0 |  | 23.8 | 27.5 | 11.6 | 6.46E+03 | | ETV |
| 3 | 63 | 12.8 | 15.2 | 12.2 | + | - | - | - | + | 0 |  | 23.1 | 29.9 | 12.3 | 6.75E+02 | | ETV |
| 4 | 65 | 21.3 | 18.7 | 7.5 | - | + | - | - | - | 0 |  | 13.3 | 25.5 | 7.1 | 4.70E+04 | | ETV |
| 5 | 58 | 18.6 | 12.8 | 8.5 | + | + | - | - | + | 0 |  | 15.7 | 13.3 | 6.9 | 2.80E+03 | | TAF |
| 6 | 68 | 11.6 | 19.3 | 14.1 | - | + | - | - | - | 0 |  | 112.2 | 122.5 | 16.9 | 5.54E+06 | | ETV |
| 7 | 55 | 9.1 | 18.8 | 4.6 | - | - | - | + | + | 0 |  | 34.5 | 20.1 | 11.2 | 1.23E+04 | | ETV |
| 8 | 65 | 14.8 | 16 | 8.2 | + | - | - | + | + | 0 |  | 35.4 | 29.4 | 12.2 | 1.42E+03 | | ETV |
| 9 | 67 | 14.9 | 20.8 | 8.2 | + | - | - | + | + | 0 |  | 6.6 | 12.5 | 20 | 1.68E+03 | | TAF |
| 10 | 56 | 16.6 | 19.8 | 13.8 | - | - | - | + | + | 0 |  | 102.8 | 106.4 | 11.7 | 8.99E+04 | | ETV |
| 11 | 63 | 43.5 | 35.9 | 10 | - | + | - | - | + | 0 |  | 34.4 | 29.6 | 6 | 7.09E+02 | | TDF |
| 12 | 44 | 11.1 | 19.5 | 5.9 | + | - | - | - | + | 0 |  | 114.5 | 95.5 | 10.8 | 5.27E+04 | | ETV |
| 13 | 48 | 75.8 | 54.9 | 8.9 | - | + | - | - | + | 0 |  | 160.9 | 90.2 | 10.66 | 5.53E+05 | | ETV |
| 14 | 63 | 11.5 | 22 | 9.6 | + | - | - | + | + | 0 |  | 20.7 | 20.2 | 6.9 | 1.01E+03 | | ETV |
| 15 | 57 | 12.7 | 15.5 | 16.5 | - | - | - | + | + | 0 |  | 10 | 15.7 | 6.6 | 5.51E+03 | | ETV |
| 16 | 56 | 12.9 | 12.3 | 9.6 | + | - | - | + | + | 0 |  | 116.4 | 66 | 16.5 | 9.15E+02 | | ETV |
| 17 | 28 | 13.4 | 26.7 | 11.7 | - | - | - | - | + | 0 |  | 38.1 | 20.8 | 8.6 | 1.57E+03 | | ETV |
| 18 | 58 | 30.2 | 27.8 | 8.7 | + | - | + | - | + | 1.45E+05 |  | 124.9 | 94.6 | 8 | 8.69E+06 | | TDF |
| 19 | 56 | 42 | 15.1 | 5.3 | - | + | - | - | + | 0 |  | 11.4 | 12.7 | 7.3 | 3.77E+03 | | ETV |
| 20 | 64 | 16 | 17.2 | 8.6 | - | + | - | + | + | 0 |  | 20.3 | 19.2 | 6.4 | 9.83E+02 | | ETV |
| 21 | 47 | 22.5 | 19.2 | 7.4 | - | + | - | - | - | 0 |  | 11.9 | 10.9 | 5.7 | 2.01E+03 | | ETV |
| 22 | 55 | 7.2 | 9.2 | 8.1 | + | + | - | - | - | 0 |  | 18.7 | 13.6 | 4 | 3.87E+03 | | ETV |
| 23 | 25 | 36.4 | 28.7 | 13.1 | - | - | - | + | + | 0 |  | 12.1 | 15.7 | 9.1 | 3.57E+03 | | ETV |
| 24 | 52 | 32.7 | 30 | 25.9 | - | - | - | - | + | 0 |  | 77.6 | 18.6 | 2.7 | 4.04E+04 | | TAF |
| 25 | 75 | 16.6 | 16.3 | 3.9 | - | - | - | - | + | 0 |  | 56.8 | 36.4 | 25 | 5.67E+03 | | ETV |
| 26 | 58 | 9.8 | 30.7 | 8.5 | + | + | - | - | + | 0 |  | 8.1 | 17.1 | 2.5 | 2.24E+03 | | ETV |
| 27 | 24 | 19.8 | 17.2 | 10.1 | - | - | - | - | + | 0 |  | 134 | 133.6 | 26.3 | 7.81E+07 | | TAF |
| 28 | 46 | 21.7 | 46.6 | 8.1 | - | - | - | - | + | 0 |  | 97.2 | 88.8 | 15.9 | 4.87E+05 | | ETV |
| 29 | 55 | 32 | 22.8 | 8.3 | + | - | - | - | + | 0 |  | 58.1 | 13.5 | 5.1 | 3.49E+03 | | ETV |
| 30 | 46 | 15.3 | 20.2 | 17.7 | - | - | - | + | + | 0 |  | 8 | 13.1 | 5.6 | 2.89E+04 | | ETV |
| 31 | 59 | 27.8 | 55.2 | 3.5 | - | + | - | - | + | 0 |  | 27.6 | 30 | 7.3 | 1.27E+03 | | ETV |
| 32 | 45 | 33.4 | 27.4 | 13.1 | - | - | - | - | + | 0 |  | 78 | 63.2 | 15 | 1.78E+04 | | ETV |
| 33 | 52 | 39.2 | 38.2 | 6.4 | + | - | - | - | + | 0 |  | 76.8 | 14.3 | 4.4 | 9.32E+03 | | ETV |

ALT, glutamic-pyruvic transaminase; AST, glutamic oxalacetic transaminase; TBIL, serum total bilirubin; ETV, entecavir, TDF, tenofovir disoproxil fumarate, TAF, tenofovir alafenamide fumarate.